Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis
Open Access
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosisAsian Journal of Andrology, 2015
- Long-Term Survival After Treatment with Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients with Cisplatin-Refractory and/or Multiply Relapsed Germ Cell TumorsEuropean Urology, 2011
- Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line ChemotherapyJournal of Clinical Oncology, 2010
- TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor AnalysisJournal of Clinical Oncology, 2010
- High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumorsAnnals of Oncology, 2009
- Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study GroupAnnals of Oncology, 2007
- High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell TumorsNew England Journal of Medicine, 2007
- Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study GroupJournal of Clinical Oncology, 2002
- Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell CancerJournal of Clinical Oncology, 2000